Laura Jean Johnston MD

Hematology•Stanford, CA

Hematologic Oncology

Associate Professor, Medicine - Blood & Marrow Transplantation, Stanford University Medical Center

Join to View Full Profile

300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Fax+1 650-725-8950

Education & Training

University of California (San Francisco)/FresnoFellowship, Hematology and Medical Oncology, 1995
University of California (San Francisco)Internship, Internal Medicine, 1989 - 1990
University of Minnesota Medical SchoolClass of 1989

Certifications & Licensure

CA State Medical License 1990 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Bone Marrow Grafting for Leukemia and Lymphoma
ENROLLING_BY_INVITATION
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Start of enrollment: 2006 Nov 01
Completed
Phase 3
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML Start of enrollment: 2008 Aug 14
Completed
Phase 1, Phase 2
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Start of enrollment: 2008 Oct 01
Completed
Phase 3
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Start of enrollment: 2011 Sep 01
Completed
Phase 1, Phase 2
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Start of enrollment: 2011 Mar 01
Completed
Phase 2
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell Start of enrollment: 2012 Feb 09
COMPLETED
PHASE1, PHASE2
Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD Start of enrollment: 2013 Jul 01
Completed
Phase 1
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases Start of enrollment: 2019 Aug 15
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
Join now to see all

Publications & Presentations

PubMed

Kidney Function after Hematopoietic Cell Transplantation with Orca-T, Cyclophosphamide or Methotrexate GvHD Prophylaxis: a single-center retrospective study.
Susan Ziolkowski, Alejandro Villar-Prados, Gomathy Parvathinathan, Nneayo Okabuonye, Siddhartha Thammineni Reddy
Transplantation and Cellular Therapy. 2025-11-09
1 citations
Bronchiectasis in Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.
David J Epstein, Nidia Rodriguez-Ormaza, Husham Sharifi, Yu Kuang Lai, Haiwei Henry Guo
Transplantation and Cellular Therapy. 2025-11-01
2 citations
Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease.
Husham Sharifi, Carson Tyler Moss, Zayan Musa, Alexander Bell, Christian O'Donnell
Blood Advances. 2025-10-14

Abstracts/Posters

Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
Laura J Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019